Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Myovant Sciences Ltd is a biotechnology business based in the US. Myovant Sciences shares (MYOV) are listed on the NYSE and all prices are listed in US Dollars. Myovant Sciences employs 407 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$22.83|
|52-week range||$13.42 - $29.71|
|50-day moving average||$22.26|
|200-day moving average||$21.63|
|Wall St. target price||$31.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.13|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-6.89%|
|1 month (2021-08-18)||8.87%|
|3 months (2021-06-18)||8.46%|
|6 months (2021-03-18)||-5.43%|
|1 year (2020-09-18)||3.82%|
|2 years (2019-09-18)||269.42%|
|3 years (2018-09-18)||24.99|
|5 years (2016-09-15)||N/A|
|Revenue TTM||$67 million|
|Gross profit TTM||$-79,361,000|
|Return on assets TTM||-37.85%|
|Return on equity TTM||0%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
There are currently 5.1 million Myovant Sciences shares held short by investors – that's known as Myovant Sciences's "short interest". This figure is 29.2% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting Myovant Sciences shares can be evaluated.
Myovant Sciences's "short interest ratio" (SIR) is the quantity of Myovant Sciences shares currently shorted divided by the average quantity of Myovant Sciences shares traded daily (recently around 760248.58420268). Myovant Sciences's SIR currently stands at 6.71. In other words for every 100,000 Myovant Sciences shares traded daily on the market, roughly 6710 shares are currently held short.
However Myovant Sciences's short interest can also be evaluated against the total number of Myovant Sciences shares, or, against the total number of tradable Myovant Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Myovant Sciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Myovant Sciences shares in existence, roughly 60 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Myovant Sciences shares, roughly 139 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Myovant Sciences.
Find out more about how you can short Myovant Sciences stock.
We're not expecting Myovant Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Myovant Sciences's shares have ranged in value from as little as $13.42 up to $29.7083. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Myovant Sciences's is 2.8505. This would suggest that Myovant Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Myovant Sciences Ltd. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.